GlassScriptPhysician profile
Steven Trai Shinn
NPI 1144648809
$12,772.60
in general payments reported to CMS, 2019-2025
57 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,702 · 2020: $1,632 · 2021: $2,593 · 2022: $1,831 · 2023: $2,176 · 2024: $1,823 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,569.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $2,293.21 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,324.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,104.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,010.80 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $874.52 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.02 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $400.71 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $281.02 | 2019-2025 | |
| Pfizer INC. | $280.22 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $180.45 | 2019-2022 | |
| Amarin Pharma, INC. | $153.39 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $132.39 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.24 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $103.56 | 2021-2022 |
Show all 55 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.